Pomegra
Iovance Stock Plunges 32% After Lung Cancer Trial Data
Why is Iovance stock down today?
Iovance (IOVA) stock fell about 32% to near $10 on Thursday after its lung cancer trial data showed a 24.6% response rate, unchanged from earlier results despite a teaser promising positive data.
Key numbers
| Stock move | -32%$14.81 to $10.07; Investing.com shows -35.45% later [2][4] |
|---|---|
| Overall response rate | 24.6%17 of 69 patients; was 25.6% |
| KRAS wild-type response rate | 43.3%vs 11.4% for KRAS-mutant |
| Smoker subgroup response rate | 59.1%22 patients, KRAS and HER2 wild-type |
| After-hours move Wednesday | +10%+on teaser of positive data |
| Market cap | $4.34Bafter the gap down |
What happened
Iovance (IOVA) stock fell about 32% to near $10 on Thursday after its lung cancer trial data showed a 24.6% response rate, unchanged from earlier results despite a teaser promising positive data. The company had said Wednesday night that good news was coming, and shares jumped more than 10% after hours. A response rate is the share of patients whose tumors shrank. Here, 17 of 69 patients responded, versus 25.6% in the earlier, smaller group. Patients without a KRAS gene mutation did better at 43.3%, and a 22-patient subgroup reached 59.1%.
Why it matters
Iovance's lung cancer trial is a key test of whether its cell therapy, lifileucel, can treat more patients and grow beyond its current sales. The overall result did not improve, so the company is now focusing on a narrower group of patients who responded better. It plans to enroll them in a new study starting in November 2026 and to ask the FDA for approval in 2027.
Who this affects
- MarketbearishLow impact
- Biotech traders saw a sharp one-day swing in Iovance.
- CompanybearishHigh impact
- Shareholders lost about a third of their stock's value.
- CompetitorsneutralLow impact
- Small cell-therapy peers rose modestly; no clear effect.
- IndustrymixedLow impact
- Cell therapies may need patient selection to prove their value.
Iovance vs Lyell Immunopharma, Instil Bio
How we got here
Data cutoff for the updated 69-patient lung cancer results.
Iovance announces positive-data webcast; shares jump more than 10% after hours.
Update shows 24.6% response rate; stock opens at $10.70 versus $14.81 prior close.
What to watch
- POSITILITY enrollment starts, testing the 59.1% subgroup result in a larger group.2026-11
- Planned FDA filing (sBLA) for lifileucel in lung cancer.2027
Educational content only. Not investment advice.
More briefsAll briefs →
Shell Stock Rises 3.1% After $5B Share Buyback
Shell (SHEL.L) shares hit a record as profit nearly doubled to $10.8B, and the FTSE 100 gained 0.3%.
Mastercard Stock Jumps 4.5% After Q3 Earnings Beat
Mastercard (MA) earned $5.31 a share versus $5.17 expected, and rival Visa also rose 2.5% on the news.
Haleon Stock Plunges 14% to 52-Week Low After Guidance Cut
Haleon (HLN) lowered its 2026 sales growth goal to about 2.5% as weak flu demand and China hit sales.